Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …

Background: Little is known about the treatment outcomes of secukinumab in clinical
practice, which differ from those in clinical trials. The effectiveness of biologics may differ in …

A number of randomized controlled trials and real‐world studies have demonstrated the
effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis …

Background Few studies have investigated the long‐term outcomes of secukinumab in real‐
life psoriasis treatment where diverse patient profiles require a personalized approach …

Background: Long term data on the real-life use of secukinumab are scant. The aim of this
study was to investigate the real-life effectiveness, safety and treatment persistence of …

Background: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the
Chinese population. Many patients are not well controlled by conventional treatments, thus …

Psoriasis is a chronic inflammatory skin disease with high rate of recurrence. New anti-
interleukin-17 (IL-17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove …

Introduction Secukinumab has demonstrated sustained long-term efficacy with a favourable
safety profile in various manifestations of psoriatic disease. We investigated effectiveness …

Abstract Secukinumab (anti‐IL17A) is effective as treatment for moderate to severe plaque
psoriasis, but real‐life data on effectiveness and safety lack. We aimed to present real‐life …

Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO)
have been demonstrated in randomized clinical trials (RCTs). However, data regarding its …